Teva Respiratory has announced that it will provide assistance to patients affected by the impending phase out of the OTC Primatene Mist epinephrine inhaler. In addition to providing educational resources, the company says that it will offer financial assistance programs and samples of its ProAir HFA albuterol and QVar HFA beclamethasone metered dose inhalers.
Teva Respiratory Executive VP and General Manager Mark Salyer commented, “As a leader in the respiratory space, Teva Respiratory is committed to providing valuable patient assistance programs to ensure asthma patients have access to treatment options, and along with their healthcare professional, are properly treating and managing their condition.“
To qualify, patients must have a prescription for the inhalers; be residents of the US, Puerto Rico, or the Virgin Islands; have incomes of 200% or less of the federal poverty rate for their state; and not be eligible for prescription drug benefits through any other plan. Information about free samples and the financial assistance program, which provides free ProAir and QVar MDIs to qualified patients, is available at the ProAir website or by telephone at 1-877-254-1039.
Read the Teva press release.
